Bristol Myers Squibb to Acquire RayzeBio for $4.1 Billion, Strengthening Oncology Portfolio
Key Highlights Bristol Myers Squibb to acquire RayzeBio for $62.50 per share, valuing the deal at approximately $4.1 billion.…
Browsing Tag
RayzeBio
1 post